Optimal Stent Selection for the Femoropopliteal Artery (SFA)

August 26, 2023 updated by: University of Nebraska
Angioplasty and stenting for atherosclerotic occlusive disease in the arteries supplying the legs (Peripheral Arterial Disease, PAD) is the most common endovascular procedure outside of the heart, but carries the highest rate of reconstruction failure. The underlying reasons for these poor results are not completely clear, but the main arterial segment within the leg, the femoropopliteal artery, appears to be significantly different from other peripheral arteries because the Superficial Femoral Artery (SFA) and Popliteal Artery (PA) that comprise the femoropopliteal artery (FPA) segment, undergo large deformations during flexion of the limb. We propose to build mathematical models of human FPAs repaired with several frequently used PAD stents. These mathematical models would be able to assess the mechanical stress in the stented SFA and PA associated with limb flexion and predict disease recurrence for arteries with different patient and lesion characteristics. Results of model predictions will be validated in patients with PAD stents who have received these stents as part of their standard of care.

Study Overview

Status

Terminated

Intervention / Treatment

Detailed Description

This is an observational study of PAD patients that have already received SFA and PA stents as part of their standard of care.

The purpose of this study is to determine the effects of Peripheral Artery Disease (PAD) stenting on the femoropopliteal artery. This will be achieved through the following Specific Aims:

Aim 1. Evaluate pre-operative lower extremity CTAs of patients with PAD and determine the baseline arterial geometry and lesion characteristics.

Aim 2. Evaluate the results of intraoperative angiography and blood pressure measurements proximal and distal to the stent.

Aim 3. After stenting perform post-operative lower extremity CTA and assess the amount of in-stent restenosis and changes to the arterial geometry.

We propose to build mathematical models of human femoropopliteal arteries repaired with several of the most commonly used PAD stents and assess the mechanical stress associated with limb flexion. These models will aim at predicting disease recurrence for arteries with different patient and lesion characteristics.

Study Type

Observational

Enrollment (Actual)

5

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Nebraska
      • Omaha, Nebraska, United States, 68198
        • University of Nebraska Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with severe peripheral artery disease already treated with a stent.

Description

Inclusion Criteria:

  • Subjects eligible for participating in this study are patients with severe PAD who have:

    1. endovascular repair of their femoropopliteal artery
    2. standard pre-operative contrast-enhanced thin-section CTA of the lower extremities
    3. intraoperative angiograms and blood pressure measurements proximal and distal to the stent during the endovascular repair
    4. no aneurysmal disease of the target femoropopliteal artery
    5. no prior open or endovascular repair of the target femoropopliteal artery (patients with re-interventions are not eligible)
    6. at least 2 out of 3 patent crural outflow vessels
    7. life expectancy >6 months
    8. no iodinated contrast allergy
    9. creatinine less than 1.6 g/dL (unless on chronic dialysis, dialysis patients are eligible)
    10. no orthopedic prostheses in the region of interest
    11. ability to comply with 6-12-month follow-up contrast enhanced thin-section CTA

Exclusion Criteria:

  1. no endovascular repair of the femoropopliteal artery
  2. endovascular or open re-intervention in the target limb
  3. no pre-operative thin-section contrast-enhanced CTA of the target limb
  4. no intraoperative angiogram or blood pressure measurements proximal and distal to the stent
  5. aneurysmal disease of the target femoropopliteal artery
  6. less than 2 patent crural outflow vessels
  7. life expectancy ≤ 6 months
  8. iodinated contrast allergy
  9. orthopedic prosthesis in the region of interest
  10. creatinine greater than 1.6 g/dL (unless dialysis patient, chronic dialysis patients are eligible)
  11. inability to comply with 6-12-month contrast-enhanced CTA follow-up requirement
  12. patient belongs to vulnerable population, i.e. pregnant women, prisoners, institutionalized individuals

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Peripheral artery disease patients
Patients with peripheral artery disease who were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have a stent in their femoropopliteal artery) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for 6-12 months. During the follow-up, a post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.
All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Radius of the femoropopliteal artery lumen
Time Frame: 6-12 months
Radius of the femoropopliteal artery lumen will be measured using follow-up CTA to assess narrowing of the artery after stent implantation.
6-12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jason MacTaggart, MD, University of Nebraska

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 2, 2014

Primary Completion (Actual)

April 16, 2021

Study Completion (Actual)

April 16, 2021

Study Registration Dates

First Submitted

November 9, 2015

First Submitted That Met QC Criteria

November 9, 2015

First Posted (Estimated)

November 11, 2015

Study Record Updates

Last Update Posted (Actual)

August 29, 2023

Last Update Submitted That Met QC Criteria

August 26, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 0386-14-FB
  • 5R01HL125736-05 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Femoropopliteal Stenting

Clinical Trials on follow-up CTA

3
Subscribe